Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,037 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06717750RecruitingPhase 1
Study of a new drug for advanced solid tumors
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT06726564RecruitingPhase 1
Study of MT027 for malignant pleural effusion
This trial tests a new drug called MT027 for people with advanced cancer that has spread to the lining around the lungs (pleura) and caused fluid buildup. The drug targets a marker on cancer cells called B7-H3. It may help control the fluid and the cancer.
BeijingAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06764771RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new investigational drug, BMS-986488, alone or with another drug (adagrasib), for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and works against certain cancers.
Hackensack, New JerseyAges 18 years+ - NCT06883539RecruitingPhase 1
Study of LXP1788 for advanced solid tumors
This trial tests a new drug called LXP1788 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how it affects the body.
TaichungAges 18 years+ - NCT06944444RecruitingPhase 1
Testing a new drug for advanced tumors
This trial tests a new drug, SSS59, in people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how it affects the body.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Newport Beach, CaliforniaAges 18 years+ - NCT06997029RecruitingPhase 1
Study of BMS-986500 for advanced solid tumors
This trial tests a new drug called BMS-986500, alone or with other treatments, for people with advanced solid tumors that cannot be removed by surgery or have spread. It aims to see if the drug is safe and effective.
Birmingham, AlabamaAges 18 years+ - NCT07036133RecruitingPhase 1
Study of Pralatrexate in patients with advanced cancer and liver problems
This trial tests a drug called pralatrexate in people with advanced solid tumors or blood cancers, including those with different levels of liver function. The goal is to understand how the drug works in the body and how safe it is for patients with various degrees of liver impairment.
Cerritos, CaliforniaAges 18 years+ - NCT07073534RecruitingPhase 1/Phase 2
A study of two drugs for advanced solid tumors
This trial tests two drugs combined—SHR-1501 and adbelizumab—for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the combination is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT07086768RecruitingPhase 1
BSI-082 alone or with T-DXd for advanced solid tumors
This trial tests a new drug, BSI-082, alone or with another drug (T-DXd), for people with advanced solid tumors that no longer respond to standard therapy. It aims to find the best dose and check how well it works.
San Antonio, TexasAges 18 years+ - NCT07148128RecruitingPhase 1/Phase 2
Testing the safety of WEF-001 for KRAS-mutant cancers
This trial studies a new drug called WEF-001 for people with advanced cancers that have a KRAS mutation. It aims to see if the drug is safe and shrinks tumors when used alone.
Dallas, TexasAges 18 years+ - NCT07169994RecruitingPhase 1/Phase 2
Testing YL202 with other cancer treatments for advanced solid tumors
This trial is testing a new drug called YL202 in combination with other anti-cancer treatments for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if this combination can shrink tumors or slow their growth.
Hefei, AnhuiAges 18–75 - NCT07190469RecruitingPhase 1
PQ203 for advanced solid tumors like triple-negative breast cancer
This early-phase trial tests a new drug called PQ203 for people with advanced solid tumors, including triple-negative breast cancer, that have stopped responding to standard treatments. It helps doctors learn whether the drug is safe and how it affects tumors.
Houston, TexasAges 18 years+ - NCT07195916RecruitingPhase 1
Testing a new drug for advanced solid tumors and blood cancers
This trial tests a new drug called INCA036873, which targets CD70 on cancer cells, for people with advanced solid tumors or certain blood cancers that have not responded to prior treatments. The goal is to see if it is safe and effective against these tough-to-treat cancers.
Duarte, CaliforniaAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Duarte, CaliforniaAges 16 years+ - NCT07238075RecruitingPhase 1
ADCX-020 for advanced or metastatic cancers
This trial tests a new drug, ADCX-020, for people with advanced solid tumors that have stopped responding to standard treatments. The drug targets cancer cells directly and may offer a new option when other treatments have failed.
Sydney, New South WalesAges 18 years+ - NCT07262619RecruitingPhase 1/Phase 2
Study of EIK1005 for advanced solid tumors
This study tests an experimental drug called EIK1005, either alone or combined with another drug (pembrolizumab), for people with advanced solid tumors, especially those with MSI-H or dMMR cancers (tumors that have trouble repairing their DNA). The goal is to see if it can shrink tumors or slow cancer growth.
Morristown, New JerseyAges 18 years+ - NCT05720117RecruitingPhase 1
Study drug for advanced solid tumors with limited treatments left
This Phase 1 study tests PYX-201 in people with advanced (grown or spread) solid cancers to see if it is safe and how it works. You may qualify if your cancer has had up to a couple of prior treatments and you can safely take study medicines and undergo required testing like a tumor biopsy.
Scottsdale, ArizonaAges 18 years+ - NCT07405086RecruitingPhase 4
Morning vs. afternoon immunotherapy for advanced solid tumors
This trial compares giving immunotherapy in the morning versus the afternoon to see if timing affects how well it works. It is for people with certain types of advanced or metastatic solid tumors who have not had this treatment before.
Portland, OregonAges 18 years+ - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT04879121RecruitingPhase 2
Larotrectinib for tumors with extra NTRK gene copies
This trial studies larotrectinib, a targeted medicine, in people with solid tumors that have extra copies (amplification) of the NTRK1, NTRK2, or NTRK3 gene. It’s for cancers that have already been treated with standard options or where standard options are unlikely to help.
Houston, TexasAges 16 years+ - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,037 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.